-transparent.png){kind=logo}
The antidepressant properties of S-adenosylmethionine, an endogenous methyl donor, were studied in inpatients who met the DSM-III criteria for major depression. Nine patients given intravenous S-adenosylmethionine and nine given low oral doses of imipramine were compared in a double-blind design for 14 days. The S-adenosylmethionine produced superior results by the end of the first week of treatment. By the end of the second week, 66% of the S-adenosylmethionine patients had a clinically significant improvement in depressive symptoms, compared to 22% of the imipramine patients. Side effects appeared to be fewer with S-adenosylmethionine than with imipramine during the last 5 days of the study.
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
March 1984,
The American journal of psychiatry,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
May 1990,
The American journal of psychiatry,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
December 1990,
Hepato-gastroenterology,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
January 1988,
Neuroscience and biobehavioral reviews,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
January 2020,
Psychopharmacology,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
April 2002,
Australian family physician,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
June 2005,
Clinical and investigative medicine. Medecine clinique et experimentale,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
June 1999,
Journal of hepatology,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
November 1987,
The American journal of medicine,
K M Bell, and
L Plon, and
W E Bunney, and
S G Potkin
December 1990,
Journal of neurology, neurosurgery, and psychiatry,
